Inhibition of integrin-linked kinase by angiotensin II receptor antagonist, irbesartan attenuates podocyte injury in diabetic rats

Chinese Medical Journal

Volumn 125, Issue 5, 2012, Pages 888-893

  Dai, Hou Yong ^a,b   Zheng, Min ^a   Tang, Ri Ning ^a   Ma, Kun Ling ^a   Ni, Jie ^a   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Angiotension II receptor blocker; Diabetic nephropathy; Integrin linked kinase; Podocyte injury

Indexed keywords

INTEGRIN LINKED KINASE; IRBESARTAN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ELECTRON MICROSCOPY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; MICROSCOPY; NONHUMAN; PODOCYTE INJURY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; MALE; PODOCYTES; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED SHR; TETRAZOLES;

EID: 84863357350     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.05.028     Document Type: Article

References (28)

1. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
2. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
3. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007; 9: 403-408.
4. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens 2009; 27 Suppl 5: s15-s21.
5. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001; 155: 505-510.
6. Blattner SM, Kretzler M. Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton. Curr Opin Nephrol Hypertens 2005; 14: 404-410.
7. El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi MP, Jarad G, et al. Podocyte-specific deletion of integrin-linked kinase results insevere glomerular basementmembrane alterationsand progressive glomerulosclerosis. J Am Soc Nephrol 2006; 17: 1334-1344.
8. Dai C, Stolz DB, Bastacky SI, St-Arnaud R, Wu C, Dedhar S, et al. Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17: 2164-2175.
9. Teixeira Vde P, Blattner SM, Li M, Anders HJ, Cohen CD, Edenhofer I, et al. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
10. Kretzler M, Teixeira VP, Unschuld PG, Cohen CD, Wanke R, Edenhofer I, et al. Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 2001; 15: 1843-1845.
11. Guo L, Sanders PW, Woods A, Wu C. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 2001; 159: 1735-1742.
12. Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymaltransition and renal interstitial fibrogenesis. J Clin Invest 2003; 112: 503-516.
13. Liu BC, Xia HL, Wu JN, Zhang XL, Liu DG, Gong YX. Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction. Acta Pharmacol Sin 2007; 28: 1810-1818.
14. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313-320.
15. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
18. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; 106: S36-S42.
19. Novak A, Hsu SC, Leung-Hagesteijn C, Radeva G, Papkoff J, Montesano R, et al. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A 1998; 95: 4374-4379.
20. Oloumi A, McPhee T, Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 2004; 1691: 1-15.
21. Kretzler M. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech 2002; 57: 247-253.
22. Han SY, Kang YS, Jee YH, Han KH, Cha DR, Kang SW, et al. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 2006; 323: 321-332.
23. Floege J, Alpers CE, Sage EH, Pritzl P, Gordon K, Johnson RJ, et al. Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. Lab Invest 1992; 67: 486-497.
24. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, et al. Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005; 16: 2953-2966.
25. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172: 299-308.
26. Kang YS, Li Y, Dai C, Kiss LP, Wu C, Liu Y. Inhibition of integrin-linked kinase blocks podocyte epithelialmesenchymal transition and ameliorates proteinuria. Kidney Int 2010; 78: 363-373.
27. Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K, et al. Epithelial-mesenchymal transition as an explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54: 653-664.
28. Li Y, Tan X, Dai C, Stolz DB, Wang D, Liu Y. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 1907-1918.